Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity
INTRODUCTION Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
have been circulating worldwide since the beginning of the pandemic. Some are termed …
have been circulating worldwide since the beginning of the pandemic. Some are termed …
[PDF][PDF] In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies
…, RS Baric, P Acharya, BF Haynes, KO Saunders - Cell, 2021 - cell.com
SARS-CoV-2-neutralizing antibodies (NAbs) protect against COVID-19. A concern regarding
SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we isolated …
SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we isolated …
[HTML][HTML] Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses
KO Saunders, E Lee, R Parks, DR Martinez, D Li… - Nature, 2021 - nature.com
Betacoronaviruses caused the outbreaks of severe acute respiratory syndrome (SARS) and
Middle East respiratory syndrome, as well as the current pandemic of SARS coronavirus 2 (…
Middle East respiratory syndrome, as well as the current pandemic of SARS coronavirus 2 (…
Targeted selection of HIV-specific antibody mutations by engineering B cell maturation
INTRODUCTION A major goal of HIV-1 vaccine development is the design of immunogens
that induce broadly neutralizing antibodies (bnAbs). However, vaccination of humans has not …
that induce broadly neutralizing antibodies (bnAbs). However, vaccination of humans has not …
[PDF][PDF] A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice
SARS-CoV-2 infection has emerged as a serious global pandemic. Because of the high
transmissibility of the virus and the high rate of morbidity and mortality associated with COVID-19…
transmissibility of the virus and the high rate of morbidity and mortality associated with COVID-19…
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
…, J Cha, S Vizel, M Babapulle, A Lamy, K Saunders… - The Lancet, 2018 - thelancet.com
Background Patients with peripheral artery disease have an increased risk of cardiovascular
morbidity and mortality. Antiplatelet agents are widely used to reduce these complications. …
morbidity and mortality. Antiplatelet agents are widely used to reduce these complications. …
[HTML][HTML] Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
BF Haynes, K Wiehe, P Borrow, KO Saunders… - Nature Reviews …, 2023 - nature.com
After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …
There are many reasons why the development of a potent and durable HIV-1 vaccine is …
Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses
…, DC Montefiori, JL Lobby, KO Saunders… - Journal of Experimental …, 2018 - rupress.org
T follicular helper (Tfh) cells are required to develop germinal center (GC) responses and
drive immunoglobulin class switch, affinity maturation, and long-term B cell memory. In this …
drive immunoglobulin class switch, affinity maturation, and long-term B cell memory. In this …
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
…, S Vizel, M BABAPULLE, A LAMY, K SAUNDERS… - The Lancet, 2018 - thelancet.com
Background Coronary artery disease is a major cause of morbidity and mortality worldwide,
and is a consequence of acute thrombotic events involving activation of platelets and …
and is a consequence of acute thrombotic events involving activation of platelets and …
Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
…, SD Schmidt, JP Todd, SR Penzak, KO Saunders… - Nature, 2014 - nature.com
To protect against human immunodeficiency virus (HIV-1) infection, broadly neutralizing
antibodies (bnAbs) must be active at the portals of viral entry in the gastrointestinal or …
antibodies (bnAbs) must be active at the portals of viral entry in the gastrointestinal or …